| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.35 | 2e-11 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.28 | 6e-08 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.1 | 0.07 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.088 | 0.09 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.075 | 0.2 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.07 | 0.2 |